Conditioning neoadjuvant therapies for improved immunotherapy of cancer

Zachary Benson, Saeed H. Manjili, Mehran Habibi, Georgi Guruli, Amir A. Toor, Kyle K. Payne, Masoud H. Manjili

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Recent advances in the treatment of melanoma and non-small cell lung cancer (NSCLC) by combining conventional therapies with anti-PD1/PD-L1 immunotherapies, have renewed interests in immunotherapy of cancer. The emerging concept of conventional cancer therapies combined with immunotherapy differs from the classical concept in that it is not simply taking advantage of their additive anti-tumor effects, but it is to use certain therapeutic regimens to condition the tumor microenvironment for optimal response to immunotherapy. To this end, low dose immunogenic chemotherapies, epigenetic modulators and inhibitors of cell cycle progression are potential candidates for rendering tumors highly responsive to immunotherapy. Next generation immunotherapeutics are therefore predicted to be highly effective against cancer, when they are used following appropriate immune modulatory compounds or targeted delivery of tumor cell cycle inhibitors using nanotechnology.

Original languageEnglish (US)
Pages (from-to)12-17
Number of pages6
JournalBiochemical Pharmacology
StatePublished - Dec 1 2017


  • Cancer immunotherapy
  • Nanoparticles
  • Neoadjuvant therapy
  • Targeted drug delivery

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology


Dive into the research topics of 'Conditioning neoadjuvant therapies for improved immunotherapy of cancer'. Together they form a unique fingerprint.

Cite this